Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

20 clinical trials · Condition

Sort:Newest first Oldest first

◉ Watch Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Record	Firm	Date
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (NCT04799275)	National Cancer Institute (NCI)	2021-05-20
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma (NCT04257578)	University of Washington	2020-12-02
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma (NCT04231877)	University of Washington	2020-10-27
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (NCT04205838)	Jonsson Comprehensive Cancer Center	2020-03-04
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (NCT03984448)	National Cancer Institute (NCI)	2019-10-22
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients (NCT03850028)	University Medical Center Groningen	2019-05-22
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (NCT03038672)	National Cancer Institute (NCI)	2018-12-21
Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma (NCT03656835)	Ohio State University Comprehensive Cancer Center	2018-09-26
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02706405)	Fred Hutchinson Cancer Center	2016-11-15
Expanded Access Program for Epcoritamab (NCT05733650)	Genmab

Track Diffuse Large B-Cell Lymphoma, Not Otherwise Specified automatically

Every clearance here is in the API, with alerts when new ones post.